In this issue of Blood, Aljoufi et al1 report that physiologic oxygen tension or “physioxia” downmodulates ten-eleven translocation 2 (Tet2) activity in hematopoietic stem cells (HSCs) and Tet2 regulates HSC differentiation and loss of HSC self-renewal that occurs in response to ambient air.
HSC transplantation provides curative therapy for patients with a variety of hematologic diseases.2 Mantel et al3 previously demonstrated that the usual collection and processing of HSCs in ambient air (∼21% O2) decreases the recovery of HSCs because of extraphysiologic oxygen shock/stress response, which produces increased reactive oxygen species (ROS) and activates mitochondrial permeability transition pores (MPTP). Mantel et al3 further described that collection of murine or human HSCs in physioxia (∼3% O2) substantially increased recovery of HSCs capable of long-term repopulation. This discovery provided the potential for improved methods for human HSC transplantation and human HSC gene editing.4 Aljoufi et al have now elucidated a molecular key that regulates the HSC response to changes in oxygen tension.
In the Aljoufi et al study, the authors performed single-cell RNA-sequencing of HSCs in physioxia and ambient air and determined that expression of the epigenetic modifier Tet2, an α-ketoglutarate (α-KG)-, iron-, and oxygen-dependent dioxygenase that converts 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC),5 was downregulated in HSCs in physioxia (see figure). Importantly, upon exposure to ambient air, wild-type HSCs displayed increased myeloid differentiation and loss of competitive repopulating capacity, whereas Tet2−/− HSCs maintained both multilineage potential and competitive repopulating capacity. Furthermore, physioxia had no significant effect on Tet2−/− HSCs, which maintained long-term competitive repopulating capacity in both ambient air and physioxia. Taken together, these data suggest that physioxia promotes HSC self-renewal, at least in part, through downregulation of Tet2.
Through its role as an epigenetic modifier, Tet2 regulates HSC differentiation to myeloid and erythroid lineages,6 and deletions and loss-of-function mutations in Tet2 occur in 10% to 20% of patients with myelodysplastic diseases and acute myeloid leukemia.7 Tet2 mutations are also commonly observed in clonal hematopoiesis of indeterminate potential.8 Animal models have confirmed that loss of Tet2 produces increased HSC self-renewal and expansion of the HSC pool coupled with splenomegaly and extramedullary hematopoiesis, which is consistent with myeloid transformation.7 In their study, Aljoufi et al show that Tet2 also plays an essential role in promoting HSC differentiation in response to oxygen stress. To confirm this point, the authors abrogated the effects of physioxia on wild-type HSCs via supplementation with α-KG, which as a cofactor for Tet2, augmented Tet2 activity, increased conversion of 5-mC to 5-hmC, and increased HSC differentiation.
The results of the Aljoufi et al study raise several interesting questions: first, Does physioxia sustain HSC numbers and HSC self-renewal capacity solely by inhibition of Tet2-mediated oxidation of 5-mC to 5-hmC? Or does physioxia also suppress other important Tet2 epigenetic functions (eg, histone modification via regulation of O-linked β-N-acetylglucosamine transferase)?9 Furthermore, How does the function of Tet2 in regulating the HSC response to oxygen shock/stress relate to the function of cyclophilin D, which Mantel et al3 previously demonstrated to have an integral role in promoting MPTP induction, ROS generation, and HSC loss in ambient air?
The application of physioxia conditions could improve HSC transplantation or HSC gene editing, but it raises practical challenges. The results of the Aljoufi et al study suggest that targeting the molecular mechanisms underpinning physioxia could, in principle, sustain HSC numbers and function ex vivo. Interestingly, Guan et al10 recently described a Tet-specific inhibitor that produced synthetic lethality for Tet2-mutant myeloid neoplastic cells while displaying no pro-proliferative effects on normal hematopoietic progenitor cells. Although even temporary inhibition of the Tet2 tumor suppressor in HSCs would require caution, an alternative strategy could utilize supplementation with 2-hydroxyglutarate, which antagonizes α-KG as a co-factor for Tet2 dioxygenase,6 thereby inhibiting Tet2 enzymatic activity and mimicking physioxia. The article by Aljoufi et al provides an important step toward understanding the molecular mechanisms that govern the HSC response to extraphysiologic stress and how such mechanisms might be targeted.
Supplementary Material
Footnotes
Conflict-of-interest disclosure: J.C.P. declares no competing financial interests.
REFERENCES
- 1.Aljoufi A, Zhang C, Ropa J, et al. Physioxia-induced downregulation of Tet2 in hematopoietic stem cells contributes to enhanced self-renewal. Blood. 2022;140(11):1263-1277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Bhatia S, Dai C, Landier W, et al. Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades: a blood or marrow transplant survivor study report. JAMA Oncol. 2021;7(11):1626-1634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Mantel CR, O’Leary HA, Chitteti BR, et al. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell. 2015;161(7):1553-1565. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Haltalli MLR, Wilkinson AC, Rodriguez-Fraticelli A, Porteus M. Hematopoietic stem cell gene editing and expansion: state-of-the-art technologies and recent applications. Exp Hematol. 2022;107:9-13. [DOI] [PubMed] [Google Scholar]
- 5.Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. 2011;333(6047):1300-1303. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Kunimoto H, Nakajima H. TET2: a cornerstone in normal and malignant hematopoiesis. Cancer Sci. 2021;112(1):31-40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Chen Q, Chen Y, Bian C, Fujiki R, Yu X. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature. 2013; 493(7433):561-564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Guan Y, Tiwari AD, Phillips JG, et al. A therapeutic strategy for preferential targeting of Tet2 mutant and Tet-dioxygenase deficient cells in myeloid neoplasms. Blood Cancer Discov. 2021; 2(2):146-161. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.